Purchase this article with an account.
Robert Raut, Neal Palejwala, Sujit Itty, Mark Barakat; Does OCT angiography provide biomarkers of visual outcome in the treatment of exudative AMD?. Invest. Ophthalmol. Vis. Sci. 2017;58(8):39.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Optical Coherence Tomography (OCT) has provided us with imaging biomarkers, such as subretinal fluid or intra-retinal fluid, useful in predicting the visual outcome of anti-VEGF treatment for age-related macular degeneration (AMD). Can the presence or location of choroidal neovascularisation (CNV) blood flow on OCT Angiography (OCTA) provide additional insights into the visual outcome of this pathology?
Retrospective study of OCTA imaging features obtained in patients undergoing anti-VEGF treatment of CNV secondary to AMD. Patients were divided in two groups: those presenting 20/50 or better vision (n=66) and those presenting 20/60 or worse vision (n=25), following more than 12 months of treatment. Each patient contributed one eye to the study. A two-tailed z-score for two independent population proportions was used to compare the incidence of each imaging feature between groups.
CNV flow on OCTA, while present in the majority of patients was not significantly more so in those with poor vision (92%) than in those with good vision (83%, p=0.276). Among the patients presenting CNV flow on OCTA, the proportion of those with fovea-sparing flow was not statistically different between patients with poor vision (26%) and those with good vision (38%, p=0.308). On structural OCT, pigment epithelial detachment and subretinal fluid were equally present in patients with good vision and those with poor vision. Intra-retinal fluid and outer retinal atrophy were more prevalent in patients with poor vision (60% and 84% respectively) than in those with good vision (33%, p=0.019 and 50%, p=0.003 respectively).
The presence of intra-retinal fluid and outer retinal atrophy was associated with poor vision. CNV blood flow was evidenced on OCTA in most patients with exudative AMD. The location and presence of CNV however were not associated with better or worse visual outcome of treatment.
This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.
This PDF is available to Subscribers Only